PMID- 18311687
OWN - NLM
STAT- MEDLINE
DCOM- 20080513
LR  - 20131121
IS  - 0176-3679 (Print)
IS  - 0176-3679 (Linking)
VI  - 41
IP  - 2
DP  - 2008 Mar
TI  - Serum concentrations of nerve growth factor and brain-derived neurotrophic factor 
      in depressed patients before and after antidepressant treatment.
PG  - 66-71
LID - 10.1055/s-2007-1004594 [doi]
AB  - INTRODUCTION: Stress, glucocorticoids and anti-depressant treatment have been 
      found to modulate the expression of brain-derived neurotrophic factor (BDNF) and 
      nerve growth factor (NGF). Recent research suggests that serum BDNF concentration 
      is reduced in depression and that successful antidepressant treatment leads to an 
      increase in serum BDNF concentration. METHODS: We studied depressed patients 
      receiving a standardized antidepressant treatment with either 150 mg 
      amitriptyline (n=20) or 40 mg paroxetine (n=20) for 36 days in a prospective 
      design. Changes in the concentrations of serum neurotrophins and salivary 
      cortisol in response to antidepressant treatment were assessed. RESULTS: 
      Independent of clinical efficacy there was a significant 'treatment' by 
      'medication' interaction effect on BDNF serum concentrations that indicated a 
      decline of BDNF by 12% in paroxetine-treated patients while there was an increase 
      by 13% in amitriptyline-treated patients. Neither antidepressant altered NGF 
      concentrations. The changes in cortisol and neurotrophin concentrations were not 
      related. DISCUSSION: Changes in BDNF serum concentrations as a result of 
      antidepressant therapy depend on the antidepressant instead of being a general 
      characteristic of response to antidepressant treatment.
FAU - Hellweg, R
AU  - Hellweg R
AD  - Central Institute of Mental Health, Mannheim, Germany. rainer.hellweg@charite.de
FAU - Ziegenhorn, A
AU  - Ziegenhorn A
FAU - Heuser, I
AU  - Heuser I
FAU - Deuschle, M
AU  - Deuschle M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Pharmacopsychiatry
JT  - Pharmacopsychiatry
JID - 8402938
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 1806D8D52K (Amitriptyline)
RN  - 41VRH5220H (Paroxetine)
RN  - 9061-61-4 (Nerve Growth Factor)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Amitriptyline/therapeutic use
MH  - Antidepressive Agents/*therapeutic use
MH  - Antidepressive Agents, Second-Generation/therapeutic use
MH  - Antidepressive Agents, Tricyclic/therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Depressive Disorder/*blood/*drug therapy/psychology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydrocortisone/metabolism
MH  - Male
MH  - Middle Aged
MH  - Nerve Growth Factor/*blood
MH  - Paroxetine/therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Saliva/metabolism
EDAT- 2008/03/04 09:00
MHDA- 2008/05/14 09:00
CRDT- 2008/03/04 09:00
PHST- 2008/03/04 09:00 [pubmed]
PHST- 2008/05/14 09:00 [medline]
PHST- 2008/03/04 09:00 [entrez]
AID - 10.1055/s-2007-1004594 [doi]
PST - ppublish
SO  - Pharmacopsychiatry. 2008 Mar;41(2):66-71. doi: 10.1055/s-2007-1004594.